Leah R. Neufeld - 13 Mar 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: CHIEF PEOPLE OFFICER
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld
Issuer symbol: IMRX
Transactions as of: 13 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 16:46:41 UTC
Previous filing: 05 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Neufeld Leah R	CHIEF PEOPLE OFFICER	245 MAIN STREET, SECOND FLOOR, CAMBRIDGE	/s/ Michael D. Bookman, Attorney-in-Fact for Leah R. Neufeld	17 Mar 2026	0001950673

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMRX	Class A Common Stock	Award		+3,628	+14%	$4.29^*	29,598	13 Mar 2026	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
F2	The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.
F3	In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.